אינפנריקס - HIB Израиль - иврит - Ministry of Health

אינפנריקס - hib

glaxo smith kline (israel) ltd - diphtheria toxoid 30 iu / 0.5 ml; filamentous haemogglutinin (fha) 25 mcg / 0.5 ml - powder and suspension for suspension for injection - tetanus toxoid, combinations with diphtheria toxoid - active immunisation of all infants from the age of 2 months to 7 years of age against diptheria, tetanus, pertussis (dtp) and hib.

וקסיגריפ לילדים Израиль - иврит - Ministry of Health

וקסיגריפ לילדים

medici ltd - a/california/7/2009 (h1n1) 7.5 mcg/dose; a/victoria/361/2011 (h3n2) 7.5 mcg/dose - suspension for injection - influenza, inactivated, whole virus - for the prevention of influenza, particularly in children aged from 6 to 35 months who run an increased risk of associated complications.

פלומיסט קואדריוואלנט Израиль - иврит - Ministry of Health

פלומיסט קואדריוואלנט

astrazeneca (israel) ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - ספריי לאף - b/phuket/3073/2013 (b/yamagata lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/darwin/9/2021 (h3n2)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 7 ±0.5 log10 ffu^a / 0.2 ml - influenza, inactivated, split virus or surface antigen - influenza, purified antigen - flumist quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza a subtype viruses ad type b viruses contained in the vaccine. flumist quadrivalent is approved for use in persons 2 through 49 years of age.

פלואריקס Израиль - иврит - Ministry of Health

פלואריקס

glaxo smith kline (israel) ltd - a/california/7/2009 (h1n1) 15 mcg / 0.5 ml; a/victoria/361/2011 (h3n2) 15 mcg / 0.5 ml - suspension for injection - influenza, live attenuated - prophylaxis of influenza, especially those who run an increased risk of associated complications. fluarix is indicated in adults and children from 6 months of age.

אווקסים פדיאטרי 80 U Израиль - иврит - Ministry of Health

אווקסים פדיאטרי 80 u

sanofi israel ltd - hepatitis a vaccines - תרחיף להזרקה - hepatitis a vaccines 80 units / 0.5 ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - avaxim 80 u pediatric is indicated for active immunisation against infection caused by hepatitis a virus in children aged from 12 months to 15 years inclusive, who are at risk either of contaminating or spreading infection or of a life threatening disease if infected.

ווקטה 25  יחידות  0.5 מל Израиль - иврит - Ministry of Health

ווקטה 25 יחידות 0.5 מל

merck sharp & dohme (israel - 1996) company ltd, israel - hepatitis a virus antigen, inactivated - תרחיף להזרקה - hepatitis a virus antigen, inactivated 25 units / 0.5 ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in children and adolescents 12 months of age and older .

פריוריקס טטרה Израиль - иврит - Ministry of Health

פריוריקס טטרה

glaxo smith kline (israel) ltd - live attenuated measles virus; live attenuated mumps virus; live attenuated rubella virus; live attenuated varicella virus - אבקה וממס להכנת תמיסה להזרקה - live attenuated measles virus 10^ 3.0 ccid50; live attenuated mumps virus 10^ 4.4 ccid50; live attenuated rubella virus 10^ 3.0 ccid50; live attenuated varicella virus 10^ 3.3 pfu - measles, combinations with mumps, rubella and varicella, live attenuated - measles, combinations with mumps, rubella and varicella, live attenuated - priorix-tetra is indicated for active immunisation against measles, mumps, rubella and varicella in children from the age of 12 months up and including 12 years of age.

פריוריקס Израиль - иврит - Ministry of Health

פריוריקס

glaxo smith kline (israel) ltd - live attenuated measles virus; live attenuated mumps virus; live attenuated rubella virus - אבקה וממס להכנת תמיסה להזרקה - live attenuated mumps virus 10^3.7 ccid50; live attenuated rubella virus 10^3.0 ccid50; live attenuated measles virus 10^3.0 ccid50 - rubella, combinations with mumps, live attenuated - rubella, combinations with mumps, live attenuated - priorix is indicated for active immunisation of children from the age of 9 months or older, adolescents and adults against measles, mumps and rubella.

אינפנריקס אי.פי.וי. איץ'.אי.בי Израиль - иврит - Ministry of Health

אינפנריקס אי.פי.וי. איץ'.אי.בי

glaxo smith kline (israel) ltd - diphtheria toxoid; fillamentous haemagglutinin (fha); haemophilus influenzae type b polysaccharide; inactivated polio virus (ipv) type 1; inactivated polio virus (ipv) type 2; inactivated polio virus (ipv) type 3; pertactin; pertussis toxoid (pt); tetanus toxoid - אבקה ותרחיף להכנת תרחיף להזרקה - diphtheria toxoid nlt 60 iu/ml; inactivated polio virus (ipv) type 3 64 du / 1 ml; inactivated polio virus (ipv) type 2 16 du / 1 ml; inactivated polio virus (ipv) type 1 80 du / 1 ml; pertussis toxoid (pt) 50 mcg/ml; fillamentous haemagglutinin (fha) 50 mcg/ml; pertactin 16 mcg/ml; tetanus toxoid nlt 80 iu/ml; haemophilus influenzae type b polysaccharide 20 mcg/vial - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus - active immunisation in infants from the age of 2 months to 5 years against diptheria, tetanus, pertussis, poliomyelitis and haemophilus influenza type b. booster dose for children who have previously been immunised with dtp, polio and hib antigens

גמציטבין " אבווה" 200 מ"ג Израиль - иврит - Ministry of Health

גמציטבין " אבווה" 200 מ"ג

pharmalogic ltd - gemcitabine as hydrochloride 200 mg - lyophilized powder for injection - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.